The economic burden of idiopathic pulmonary fibrosis in Australia: a cost of illness study

被引：0
作者：
Ingrid A. Cox
Barbara de Graaff
Hasnat Ahmed
Julie Campbell
Petr Otahal
Tamera J. Corte
Yuben Moodley
Nicole Goh
Peter Hopkins
Sacha Macansh
E. Haydn Walters
Andrew J. Palmer
机构：
[1] University of Tasmania,Menzies Institute for Medical Research
[2] NHMRC Centre of Research Excellence for Pulmonary Fibrosis,Central Clinical School
[3] The University of Sydney,Department of Respiratory and Sleep Medicine
[4] Royal Prince Alfred Hospital,Faculty of Health and Medical Sciences
[5] The University of Western Australia,Institute of Respiratory Health
[6] The University of Western Australia,Department of Respiratory Medicine
[7] Fiona Stanley Hospital,Department of Respiratory Medicine and Sleep
[8] Alfred Hospital,Department of Respiratory and Sleep Medicine
[9] Austin Hospital,Queensland Centre for Pulmonary Transplantation and Vascular Disease
[10] The Prince Charles Hospital,Faculty of Medicine
[11] University of Queensland,Australian Idiopathic Pulmonary Fibrosis Registry
[12] Lung Foundation of Australia,undefined
来源：
The European Journal of Health Economics | 2023年 / 24卷
关键词：
Cost of illness; Idiopathic pulmonary fibrosis; Heath resource utilization; Economic burden;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1121 / 1139
页数：18
相关论文
共 148 条
  • [1] Richeldi L(2017)Idiopathic pulmonary fibrosis The Lancet. 389 1941-1952
  • [2] Collard HR(2012)Epidemiology and management of common pulmonary diseases in older persons J. Gerontol. A Biol. Sci. Med. Sci. 67 276-291
  • [3] Jones MG(2015)Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review Eur Respir J. 46 1113-1130
  • [4] Akgun KM(2017)Identification of key cost generating events for idiopathic pulmonary fibrosis: a systematic review Lung. 195 1-8
  • [5] Crothers K(2021)Cost drivers in the pharmacological treatment of interstitial lung disease Respir. Res. 22 218-727
  • [6] Pisani M(2021)Recent trends in pirfenidone and nintedanib use for idiopathic pulmonary fibrosis in Australia Aust. Health Rev. 45 718-277
  • [7] Raghu G(2019)Understanding the patient's experience of care in idiopathic pulmonary fibrosis Respirology 24 270-337
  • [8] Amatto VC(2014)Cost-of-illness studies: concepts, scopes, and methods Clin. Mol. Hepatol. 20 327-1091
  • [9] Behr J(2014)Australian idiopathic pulmonary fibrosis registry: vital lessons from a national prospective collaborative project Respirology 19 1088-2632
  • [10] Stowasser S(2021)The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia Qual. Life Res. 30 2615-224
12345678910